Abstract
Introduction:
Continuous prostacyclin infusion is the standard of care for pulmonary arterial hypertension, requiring central venous access devices where dwell time is critical but associated with complications.
Methods:
Retrospective 10-year case series of 18 adult pulmonary arterial hypertension patients managed through central venous access devices by a specialized multidisciplinary team.
Results:
Sixty-nine catheters were analyzed across 18 patients; median catheter survival estimated by the Kaplan-Meier method was 9.3 months (95% confidence interval (8.1–12)). Occlusion was the most frequent complication (1.20 per 1,000 catheter-days) and the leading removal reason across all device types. Catheter-related bloodstream infections occurred in four instances (0.22 per 1,000 catheter-days), with methicillin-susceptible Staphylococcus aureus as the only isolated pathogen. Catheter-related thrombosis was documented in two cases. Three catheters fractured, one of each device type.
Discussion:
Evidence on central venous access device outcomes in pulmonary arterial hypertension remains scarce in middle-income countries. The median dwell time observed in this series was shorter than that reported in high-income country cohorts, while catheter-related bloodstream infection and thrombosis rates were numerically lower than those documented in comparable series.
Conclusion:
In this descriptive 10-year case series from a middle-income country, long-term central venous access devices for continuous epoprostenol infusion in pulmonary arterial hypertension were associated with a prolonged dwell time and low complication rates under a structured multidisciplinary follow-up model. Larger multicenter studies are needed to confirm generalizability and identify determinants of catheter longevity.
Keywords
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
